Cor.At® pure cardiomyocytes provide a unique cellular model for hypertrophic cardiomyopathy that makes the drug discovery and development process more efficient and convenient. See also our My.Cor service.
Cor.At® stem cell-derived mouse cardiomyocytes are reliably induced to reproduce features of hypertrophic cardiomyocytes when stimulated with specific agonists.
They allow the determination of a compounds effect on hypertrophic cardiomyocytesin vitro and enable screening of large compound libraries. This system has been validated with reference drugs known to suppress cardiomyopathy (Fig.1).
Initial proof-of-concept studies have also shown that use of Cor.4U@ human iPS cell-derived cardiomyocytes work extremely well within the My.Cor system. This comes as pharmaceutical companies continue to seek more translational in vitro models of human disease. See also our My.Cor service.